MX380106B - Biomarcadores relacionados a cancer. - Google Patents

Biomarcadores relacionados a cancer.

Info

Publication number
MX380106B
MX380106B MX2019005940A MX2019005940A MX380106B MX 380106 B MX380106 B MX 380106B MX 2019005940 A MX2019005940 A MX 2019005940A MX 2019005940 A MX2019005940 A MX 2019005940A MX 380106 B MX380106 B MX 380106B
Authority
MX
Mexico
Prior art keywords
cancer
cervical cancer
biomarkers related
precancerous lesion
sample
Prior art date
Application number
MX2019005940A
Other languages
English (en)
Other versions
MX2019005940A (es
Inventor
Rojas Alberto Checa
GODÍNEZ Orlando SANTILLAN
Palestino Raúl Domínguez
Original Assignee
Timser S A P I De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Timser S A P I De C V filed Critical Timser S A P I De C V
Priority to MX2019005940A priority Critical patent/MX380106B/es
Publication of MX2019005940A publication Critical patent/MX2019005940A/es
Priority to EP20809942.4A priority patent/EP3973292A4/en
Priority to US16/879,748 priority patent/US11771740B2/en
Priority to CA3132104A priority patent/CA3132104A1/en
Priority to AU2020280245A priority patent/AU2020280245A1/en
Priority to PCT/IB2020/000395 priority patent/WO2020234647A2/en
Priority to PH1/2021/552924A priority patent/PH12021552924A1/en
Priority to SG11202110101PA priority patent/SG11202110101PA/en
Priority to JP2021556203A priority patent/JP7738256B2/ja
Priority to BR112021023247A priority patent/BR112021023247A2/pt
Priority to CN202080018686.0A priority patent/CN113597557A/zh
Priority to US17/069,744 priority patent/US11160844B2/en
Priority to US17/199,127 priority patent/US11160845B2/en
Priority to ZA2021/05583A priority patent/ZA202105583B/en
Priority to CL2021003005A priority patent/CL2021003005A1/es
Priority to CONC2021/0015641A priority patent/CO2021015641A2/es
Priority to ZA2022/07531A priority patent/ZA202207531B/en
Priority to US18/454,391 priority patent/US12433933B2/en
Publication of MX380106B publication Critical patent/MX380106B/es
Priority to JP2025138169A priority patent/JP2025176041A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere un método in vitro para el diagnóstico de una lesión precancerosa o cáncer cervical, caracterizado porque comprende el paso de: (a) detectar en una muestra de un sujeto la presencia de al menos una proteína biomarcador seleccionada de entre Farnesil pirofosfato sintasa y Ankirin-3, en donde la sobreexpresión de al menos una de dicha(s) proteína (s) biomarcado, en comparación con una muestra de control es indicativo de una lesión precancerosa o cáncer cervical.
MX2019005940A 2019-05-21 2019-05-21 Biomarcadores relacionados a cancer. MX380106B (es)

Priority Applications (19)

Application Number Priority Date Filing Date Title
MX2019005940A MX380106B (es) 2019-05-21 2019-05-21 Biomarcadores relacionados a cancer.
US16/879,748 US11771740B2 (en) 2019-05-21 2020-05-20 Methods of diagnosing and treating cervical cancer
JP2021556203A JP7738256B2 (ja) 2019-05-21 2020-05-20 子宮頸癌を診断および治療する方法
CN202080018686.0A CN113597557A (zh) 2019-05-21 2020-05-20 诊断和治疗宫颈癌的方法
CA3132104A CA3132104A1 (en) 2019-05-21 2020-05-20 Methods of diagnosing and treating cervical cancer
AU2020280245A AU2020280245A1 (en) 2019-05-21 2020-05-20 Methods of diagnosing and treating cervical cancer
PCT/IB2020/000395 WO2020234647A2 (en) 2019-05-21 2020-05-20 Methods of diagnosing and treating cervical cancer
PH1/2021/552924A PH12021552924A1 (en) 2019-05-21 2020-05-20 Methods of diagnosing and treating cervical cancer
SG11202110101PA SG11202110101PA (en) 2019-05-21 2020-05-20 Methods of diagnosing and treating cervical cancer
EP20809942.4A EP3973292A4 (en) 2019-05-21 2020-05-20 METHODS OF DIAGNOSIS AND TREATMENT OF CERVICAL CANCER
BR112021023247A BR112021023247A2 (pt) 2019-05-21 2020-05-20 Métodos de diagnóstico e tratamento do câncer cervical
US17/069,744 US11160844B2 (en) 2019-05-21 2020-10-13 Methods of diagnosing and treating cervical cancer based on expression of farnesyl pyrophosphate synthase
US17/199,127 US11160845B2 (en) 2019-05-21 2021-03-11 Methods of diagnosing and treating cervical cancer or a high-grade cervical lesion based on expression of ankyrin-3
ZA2021/05583A ZA202105583B (en) 2019-05-21 2021-08-06 Methods of diagnosing and treating cervical cancer
CL2021003005A CL2021003005A1 (es) 2019-05-21 2021-11-15 Métodos para diagnosticar y tratar el cáncer de cuello uterino
CONC2021/0015641A CO2021015641A2 (es) 2019-05-21 2021-11-22 Métodos para diagnosticar y tratar el cáncer de cuello uterino
ZA2022/07531A ZA202207531B (en) 2019-05-21 2022-07-07 Methods of diagnosing and treating cervical cancer
US18/454,391 US12433933B2 (en) 2019-05-21 2023-08-23 Methods of diagnosing cervical cancer based on altered polypeptide expression and treatment thereof
JP2025138169A JP2025176041A (ja) 2019-05-21 2025-08-21 子宮頸癌を診断および治療する方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2019005940A MX380106B (es) 2019-05-21 2019-05-21 Biomarcadores relacionados a cancer.

Publications (2)

Publication Number Publication Date
MX2019005940A MX2019005940A (es) 2019-10-11
MX380106B true MX380106B (es) 2025-03-12

Family

ID=69416620

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005940A MX380106B (es) 2019-05-21 2019-05-21 Biomarcadores relacionados a cancer.

Country Status (14)

Country Link
US (4) US11771740B2 (es)
EP (1) EP3973292A4 (es)
JP (2) JP7738256B2 (es)
CN (1) CN113597557A (es)
AU (1) AU2020280245A1 (es)
BR (1) BR112021023247A2 (es)
CA (1) CA3132104A1 (es)
CL (1) CL2021003005A1 (es)
CO (1) CO2021015641A2 (es)
MX (1) MX380106B (es)
PH (1) PH12021552924A1 (es)
SG (1) SG11202110101PA (es)
WO (1) WO2020234647A2 (es)
ZA (2) ZA202105583B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021163608A2 (en) * 2020-02-14 2021-08-19 Galaxy Ccro, Inc. Devices and methods for treating ischaemia and acute respiratory distress syndromes
CN117694546B (zh) * 2023-11-24 2025-09-19 西北农林科技大学 Fndc1蛋白促进骨骼肌再生和治疗肌肉发育相关疾病的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516089A (ja) * 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
ATE289685T1 (de) * 2003-08-25 2005-03-15 Mtm Lab Ag Verfahren zum nachweis von karzinomen in solubilisierten zervikalen körperproben
KR100943525B1 (ko) 2005-03-18 2010-02-22 (주)지노믹트리 바이오마커 스크리닝 시스템
PL2481756T3 (pl) * 2005-10-31 2018-02-28 Oncomed Pharmaceuticals, Inc. Kompozycje i sposoby diagnozowania i leczenia nowotworu
US20090221430A1 (en) * 2006-03-10 2009-09-03 Cytyc Corporation Proteomic Methods For The Identification And Use Of Putative Biomarkers Associated With The Dysplastic State In Cervical Cells Or Other Cell Types
WO2009134897A1 (en) 2008-04-29 2009-11-05 Burnham Institute For Medical Research E3-independent ubiquitinylation assay
JP5526378B2 (ja) * 2009-03-05 2014-06-18 国立大学法人山口大学 子宮頸癌の検出方法
EP2417449A4 (en) 2009-04-07 2016-07-06 Nexus Dx Inc PORTABLE SCANNER SYSTEMS AND METHOD FOR READING TEST RESULTS AT THE SERVICE
JP2013099253A (ja) * 2010-03-11 2013-05-23 Intec Systems Institute Inc 肺癌または子宮頸癌の診断マーカー
US20110224088A1 (en) * 2010-03-11 2011-09-15 Heidi Lyng Biomarkers for subtypes of cervical cancer
US20140213475A1 (en) * 2011-07-14 2014-07-31 University Of Massachusetts Methods of diagnosing cancer using epigenetic biomarkers
HK1205558A1 (en) * 2012-02-21 2015-12-18 Oslo Universitetssykehus Hf Methods and biomarkers for detection and prognosis of cervical cancer
CN105008923B (zh) * 2013-01-22 2018-03-02 新蛋白质组学公司 在癌症诊断中的血小板生物标记物
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
CN109406785A (zh) * 2017-08-18 2019-03-01 山东泽济生物科技有限公司 肿瘤血液标志物及其应用

Also Published As

Publication number Publication date
EP3973292A4 (en) 2023-07-26
US20210015892A1 (en) 2021-01-21
US20210093692A1 (en) 2021-04-01
US11160844B2 (en) 2021-11-02
ZA202105583B (en) 2023-06-28
ZA202207531B (en) 2023-12-20
CO2021015641A2 (es) 2022-01-28
CL2021003005A1 (es) 2022-07-15
JP2022533303A (ja) 2022-07-22
AU2020280245A1 (en) 2021-12-23
MX2019005940A (es) 2019-10-11
CA3132104A1 (en) 2020-11-26
SG11202110101PA (en) 2021-10-28
US20240091305A1 (en) 2024-03-21
PH12021552924A1 (en) 2022-04-11
JP7738256B2 (ja) 2025-09-12
WO2020234647A2 (en) 2020-11-26
US20210196785A1 (en) 2021-07-01
US11771740B2 (en) 2023-10-03
BR112021023247A2 (pt) 2022-01-04
US12433933B2 (en) 2025-10-07
US11160845B2 (en) 2021-11-02
CN113597557A (zh) 2021-11-02
EP3973292A2 (en) 2022-03-30
JP2025176041A (ja) 2025-12-03
WO2020234647A3 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
BR112021022879A2 (pt) Sistemas e métodos para avaliação de fração tumoral
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
BR112017025297A2 (pt) anticorpos anti-gitr para diagnóstico do câncer
MX2017001302A (es) Biomarcadores para predecir la respuesta del dlbcl al tratamiento con un inhibidor de la btk.
MX2021006791A (es) Metodos y composiciones para detectar proteinas mal plegadas.
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
EP4047372A3 (en) Lipopolysaccharide-binding protein as biomarker for non-alcoholic fatty liver disease
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies
WO2017050939A3 (en) Method and array for diagnosing pancreatic cancer in an individual
MY179845A (en) Specific biomarker set for non-invasive diagnosis of liver cancer
BR112018073214A2 (pt) métodos para a previsão do risco de recorrência da fibrilação atrial, para o diagnóstico de fibrilação atrial em um indivíduo, para o monitoramento de uma terapia e para a classificação da fibrilação e utilizações do biomarcador
MX2020002243A (es) Anticuerpos utiles en diagnosis de cancer.
ES2845150T3 (es) Diagnóstico de pancreatitis aguda (PA) mediante la detección de glicoproteína 2 isoforma alfa (GP2A)
WO2013112836A3 (en) Diagnostic and prognostic biomarkers for cancer
MX380106B (es) Biomarcadores relacionados a cancer.
MY195697A (en) Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
MX345893B (es) Ensayo para clasificación de compuestos que disminuyen selectivamente el número de células madre de cáncer.
BR112017005421A2 (pt) método in vitro para prever se pacientes com câncer são propensos a reagir a um inibidor de receptor, kit e inibidor de egfr
BR112021022532A8 (pt) Controle de variabilidade de analito entre amostras em matrizes biológicas complexas
BR112016002709A2 (pt) queratinas como biomarcadores para câncer cervical e sobrevivência
MX384636B (es) Método para detectar anticuerpos neutralizantes contra la insulina humana recombinante en suero humano.
WO2014151079A3 (en) Ratio based biomarkers and methods of use thereof for the detection and prognosis of cancer
MX2024009782A (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto.
PE20191707A1 (es) Composicion para la medicion, prevencion o alivio del envejecimiento de la piel usando hapln1